A hepatitis B vaccine formulated with a novel adjuvant system
| Autor: | Gerhard Wiedermann, N. Garcon, F. Ambrosch, C. Thiriart, Moncef Mohamed SmithKline Beecham Bio. s.a Slaoui, Isabelle Desombere, Geert Leroux-Roels, M. Kundi, S Thoelen |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
Male Hepatitis B vaccine Adolescent medicine.medical_treatment Population Immunization Secondary Pain Lymphocyte Activation medicine.disease_cause Adjuvants Immunologic Double-Blind Method Orthohepadnavirus Seroepidemiologic Studies medicine Edema Humans Hepatitis B Vaccines Hepatitis B Antibodies education Fatigue Hepatitis B virus Immunity Cellular Vaccines Synthetic education.field_of_study General Veterinary General Immunology and Microbiology biology business.industry Headache Public Health Environmental and Occupational Health Hepatitis B biology.organism_classification medicine.disease Virology Vaccination Lipid A Infectious Diseases Hepadnaviridae Immunology Alum Compounds Molecular Medicine Female Safety business Adjuvant Follow-Up Studies |
| Zdroj: | Vaccine. 18:2095-2101 |
| ISSN: | 0264-410X |
| DOI: | 10.1016/s0264-410x(99)00566-6 |
| Popis: | Although more than 95% of the vaccinated population responds to the currently licensed vaccines against hepatitis B, some groups were found to be low responders. Lipid A as adjuvant, through its ability to activate macrophages, might improve humoral as well as cellular immune response. Therefore we evaluated the profile of a hepatitis B vaccine with the new adjuvant system SBAS4. 150 young adults were enrolled and randomized into three groups: one received the SBAS4 hepatitis B vaccine, the second Engerix-B(TM) and the third a hepatitis B vaccine with an alternative formulation on alum. Vaccinations were at 0 and 6 months. The vaccine was well tolerated. At month 7 all vaccinees were protected but with significant differences in GMTs between groups: 13,271 mIU/ml for the SBAS4 group versus 1203 and 1823 mIU/ml. Hence the hepatitis B vaccine with the new adjuvant system is more immunogenic compared to the other vaccines containing the same antigen and could be suitable for a two dose schedule. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect